2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

glial cells

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

2

Biochemical Assay Reagents

4

Peptides

4

MCE Kits

2

Inhibitory Antibodies

6

Natural
Products

5

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1411
    i-Inositol
    5+ Cited Publications

    myo-Inositol; meso-Inositol

    		 Endogenous Metabolite Others
    i-Inositol (myo-Inositol) is a compound of sugar alcohols. i-Inositol is involved in a series of biological processes such as insulin signal transduction and cytoskeletal transduction. i-Inositol mainly exists in glial cells and plays an osmotic role .
    i-Inositol
  • HY-110281
    Dehydroascorbic acid

    		Endogenous Metabolite Cardiovascular Disease Neurological Disease
    Dehydroascorbic acid is an oxidized form of vitamin C that can cross the blood-brain barrier (BBB). Dehydroascorbic acid clears cytotoxic reactive oxygen species (ROS) produced after ischemic stroke by converting to ascorbic acid (AA), thereby reducing neuronal and glial cell damage and stabilizing cerebral microvascular NO signaling to maintain perfusion in the ischemic area. Dehydroascorbic acid can be used in research on ischemic stroke .
    Dehydroascorbic acid
  • HY-B0696A
    Tiagabine hydrochloride

    NO050328 hydrochloride; NO328 hydrochloride; TGB hydrochloride

    		 GABA Receptor Neurological Disease
    Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine hydrochloride
  • HY-B0696
    Tiagabine

    NO050328; NO328; TGB

    		 GABA Receptor Neurological Disease
    Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine
  • HY-148853
    SRI-42127
    1 Publications Verification

    		 HuR Others
    SRI-42127 is a HuR translocation inhibitor. HuR is an RNA regulator that binds to AREs, and HuR translocations promote the production of inflammatory cytokines in glial cells. However, SRI-42127 can destroy mRNA stability and inhibit gene promoter activation. SRI-42127 also inhibits microglial cell activation and attenuates recruitment/chemotaxis of neutrophils and monocytes .
    SRI-42127
  • HY-107521
    TFB-TBOA
    3 Publications Verification

    CF3-Bza-TBOA

    		 EAAT Neurological Disease
    TFB-TBOA (CF3-Bza-TBOA) is a potent glutamate transporter blocker that potently suppresses the activity of glial transporters. TFB-TBOA shows IC50 values of 22, 17, and 300 nM for glutamate transporters EAAT1, EAAT2, and EAAT3 respectively in an uptake assay using cells transiently expressing EAATs .
    TFB-TBOA
  • HY-W002199
    6:2 Fluorotelomer alcohol

    6:2 FTOH; 1H,1H,2H,2H-Perfluoro-1-octanol; 2-(Perfluorohexyl)ethanol

    		 Bacterial Apoptosis ERK TNF Receptor Infection Neurological Disease
    6:2 Fluorotelomer alcohol (6:2 FTOH) is an orally active, blood-brain barrier-permeable modulator of cyclin D1 and ETS1. 6:2 Fluorotelomer alcohol downregulates cyclin D1 expression, upregulates ETS1 via the TNF-α/ERK 1/2 pathway, impairs mitochondrial membrane potential and respiratory function, increases reactive oxygen species levels, disrupts calcium homeostasis and activates endoplasmic reticulum stress markers, and induces cell proliferation inhibition and endothelial-mesenchymal transition. Furthermore, 6:2 Fluorotelomer alcohol induces morphological abnormalities in zebrafish embryos and liver developmental damage, while disrupting the brain immune microenvironment in mice, causing systemic toxicity and delayed pup maturation in CD-1 mice. 6:2 Fluorotelomer alcohol also induces cortical neuron apoptosis, glial cell activation, synaptic abnormalities, colonic barrier damage, intestinal dysbiosis and autism spectrum disorder-like symptoms in mice. 6:2 Fluorotelomer alcohol shows no mutagenic, clastogenic, primary skin/eye irritation or skin sensitizing effects, exhibits no selective reproductive toxicity in CD-1 mice, and is classified as GHS Category 4 for acute oral toxicity. 6:2 Fluorotelomer alcohol can be used in studies of neurodevelopmental disorders and autism spectrum disorders .
    6:2 Fluorotelomer alcohol
  • HY-P1777
    IGF-I (24-41)

    Insulin-like Growth Factor I (24-41)

    		 IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development .
    IGF-I (24-41)
  • HY-111969
    BT18
    1 Publications Verification

    		 GDNF Receptor Neurological Disease
    BT18 is a molecule mimic with function similar to glial cell line-derived neurotrophic factor (GDNF) . BT18 shows an effect on GDNF family receptor GFRα1 and RET receptor tyrosine kinase RetA function .
    BT18
  • HY-B1197
    Amcinonide

    CL-34699

    		 Glucocorticoid Receptor NO Synthase Interleukin Related TNF Receptor Inflammation/Immunology Endocrinology
    Amcinonide is an inhibitor of NO release (IC50 = 3.38 nM). Amcinonide inhibits NNC-induced expression of the proinflammatory genes iNOS, TNF-α, and IL-1β in glial cells. Amcinonide reduces the numbers of T6+/Ia+ cells with a concomitant increase in T6+/Ia- cells. Amcinonide induces a selective reduction in expression of Ia antigens. Amcinonide can also be studied in research for eczematous dermatitis .
    Amcinonide
  • HY-139201H
    Poly-D-lysine hydrobromide (MW ≥300000)

    PDLHB (MW ≥300000)

    		 CaSR Others
    Poly-D-lysine hydrobromide (MW ≥300000) (PDLHB (MW ≥300000)) is a cationic polymer and cell adhesion promoter. Poly-D-lysine hydrobromide (MW ≥300000) serves as a substrate coating to support the adhesion and proliferation of rat dorsal root ganglion satellite glial cells in vitro. Poly-D-lysine hydrobromide (MW ≥300000) promotes the adhesion and immobilization of cells on plastic culture dishes. Poly-D-lysine hydrobromide is also known as a calcium-sensing receptor (CaSR) agonist peptide .
    Poly-D-lysine hydrobromide (MW ≥300000)
  • HY-B1411R
    i-Inositol (Standard)

    myo-Inositol (Standard); meso-Inositol (Standard)

    		 Reference Standards Endogenous Metabolite Others
    i-Inositol (Standard) is the analytical standard of i-Inositol. This product is intended for research and analytical applications. i-Inositol (myo-Inositol) is a compound of sugar alcohols. i-Inositol is involved in a series of biological processes such as insulin signal transduction and cytoskeletal transduction. i-Inositol mainly exists in glial cells and plays an osmotic role .
    i-Inositol (Standard)
  • HY-N1391
    10-Deacetyltaxol

    10-Deacetylpaclitaxel

    		 Microtubule/Tubulin Cancer
    10-Deacetyltaxol (10-Deacetylpaclitaxel) is a taxane derivative isolated from Taxus wallichiana Zucc . 10-Deacetyltaxol (10-Deacetylpaclitaxel) promotes the polymerization of tubulin and to inhibit the depolymerization of microtubules induced by cold or by calcium ions in vitro . 10-Deacetyltaxol (10-Deacetylpaclitaxel) exhibits cytotoxicity in human glial and neuroblastoma cell-lines .
    10-Deacetyltaxol
  • HY-155386
    Peroxynitrite sodium

    		Biochemical Assay Reagents Enterovirus DNA/RNA Synthesis Mitochondrial Metabolism Infection Neurological Disease
    Peroxynitrite sodium is a product of the diffusion-controlled reaction between nitric oxide and superoxide radicals, as well as an oxidant and an antiviral agent. Peroxynitrite sodium inhibits Mitochondrial respiration. Peroxynitrite sodium suppresses the replication of Coxsackievirus, partly by inhibiting viral RNA entry into host cells. Peroxynitrite sodium induces a significant nociceptive response .
    Peroxynitrite sodium
  • HY-W021450A
    DL-Fluorocitric acid barium

    		Biochemical Assay Reagents Neurological Disease
    DL-Fluorocitric acid barium is a glial cell metabolic inhibitor. DL-Fluorocitric acid barium inhibits mechanical hyperalgesia induced by subcutaneous injection of complete Freund's adjuvant in rats. DL-Fluorocitric acid barium inhibits nociceptive behaviors induced by Histamine (HY-B1204) in mice and blocks the phosphorylation of the NMDA receptor NR1 subunit in the lumbar spinal cord of mice. DL-Fluorocitric acid (barium) can be used in the research of mechanical hyperalgesia and nociceptive pain .
    DL-Fluorocitric acid barium
  • HY-116116
    Tafetinib

    SIM010603

    		 c-Kit RET VEGFR Cancer
    Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .
    Tafetinib
  • HY-P990122
    Anti-Rat IL-4 Antibody (OX-81)

    		Interleukin Related Inflammation/Immunology
    Anti-Rat IL-4 Antibody (OX-81) is an antibody inhibitor against rat IL-4. Anti-Rat IL-4 Antibody (OX-81) can specifically block the anti-inflammatory effect of IL-4. Anti-Rat IL-4 Antibody (OX-81) can be used for research on inflammation conditions such as experimental allergic encephalomyelitis (EAE) .
    Anti-Rat IL-4 Antibody (OX-81)
  • HY-P11299
    EBNA-1 (386–405 aa)

    		EBV Infection Neurological Disease Inflammation/Immunology
    EBNA-1 (386-405 aa) is a cross-reactive viral antigen peptide. EBNA-1 (386-405 aa) has a high molecular similarity to GlialCAM (370-389 aa) and it induces the production of cross-reactive antibodies that recognize both EBV antigens and glial cells in the central nervous system, thereby triggering autoimmune responses. EBNA-1 (386-405 aa) can used for Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) research .
    EBNA-1 (386–405 aa)
  • HY-P2475
    [Pro9]-Substance P

    		Neurokinin Receptor Neurological Disease
    [Pro9]-Substance P is a potent, reversible and selective agonist of NK-1 tachykinin receptors with an EC50 of 0.93 nM .
    [Pro9]-Substance P
  • HY-163840
    GFRα2/3-IN-1

    		GDNF Receptor Neurological Disease
    GFRα2/3-IN-1 (Compound 16) is a selective GFRα2/3 inhibitor with IC50 values of 0.1 and 0.2 μM for GFRα2 and GFRα3, respectively. GFRα2 is a glial cell line-derived neurotrophic factor (GDNF) receptor related to GFRα1, GFRα2/3-IN-1 can be used for pain and itch research .
    GFRα2/3-IN-1
  • HY-B0696B
    Tiagabine hydrochloride hydrate

    NO050328 hydrochloride hydrate; NO328 hydrochloride hydrate; TGB hydrochloride hydrate

    		 GABA Receptor Neurological Disease
    Tiagabine (NO050328; NO328; TGB) hydrochloride hydrate is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride hydrate exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride hydrate is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine hydrochloride hydrate
  • HY-P1777A
    IGF-I (24-41) TFA

    Insulin-like Growth Factor I (24-41) TFA

    		 IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development .
    IGF-I (24-41) TFA
  • HY-170231
    Bovine Osteopontin

    OPN

    		 Biochemical Assay Reagents Others
    Bovine Osteopontin (OPN) is a secreted highly acidic calcium-binding phosphorylated glycoprotein that is chemotactic for macrophages, smooth muscle cells, endothelial cells, and glial cells .
    Bovine Osteopontin
  • HY-P99748
    Nadecnemab

    		TGF-β Receptor Inflammation/Immunology
    Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .
    Nadecnemab
  • HY-149498
    Carbonic anhydrase inhibitor 15

    		Carbonic Anhydrase Neurological Disease Inflammation/Immunology
    Carbonic anhydrase inhibitor 15 (Compound 8) is a carbonic anhydrase inhibitor (Ki: 8.5 nM for hCA II). Carbonic anhydrase inhibitor 15 has analgesic effect .
    Carbonic anhydrase inhibitor 15
  • HY-134110
    N-Methylarachidonamide

    		Endogenous Metabolite Metabolic Disease
    Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N-methyl amide is an analog of anandamide that binds to the human central cannabinoid (CB1) receptor with a Ki of 60 nM. It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.
    N-Methylarachidonamide
  • HY-134055
    Arachidonoyl-N,N-dimethyl amide

    Arachidonic acid-N,N-dimethyl amide

    		 Cannabinoid Receptor Metabolic Disease
    Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N,N-dimethyl amide is an analog of anandamide that exhibits weak or no binding to the human central cannabinoid (CB1) receptor (Ki >1 μM). It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.
    Arachidonoyl-N,N-dimethyl amide
  • HY-B1197R
    Amcinonide (Standard)

    CL-34699 (Standard)

    		 Reference Standards Glucocorticoid Receptor NO Synthase TNF Receptor Interleukin Related Inflammation/Immunology Endocrinology
    Amcinonide (Standard) is the analytical standard of Amcinonide. This product is intended for research and analytical applications. Amcinonide is an inhibitor of NO release (IC50 = 3.38 nM). Amcinonide inhibits NNC-induced expression of the proinflammatory genes iNOS, TNF-α, and IL-1β in glial cells. Amcinonide reduces the numbers of T6+/Ia+ cells with a concomitant increase in T6+/Ia- cells. Amcinonide induces a selective reduction in expression of Ia antigens. Amcinonide can also be studied in research for eczematous dermatitis .
    Amcinonide (Standard)
  • HY-W101298S
    (Leu-13C6,15N)-Ile-OH TFA

    L-Leucyl-13C6,15N-L-isoleucine TFA

    		 Isotope-Labeled Compounds Neurological Disease
    (Leu-13C6,15N)-Ile-OH (L-Leucyl-13C6,15N-L-isoleucine) TFA is the deuterium labeled Leu-Ile-OH. Leu-Ile-OH protects against neuronal death by inducing brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) synthesis .
    (Leu-13C6,15N)-Ile-OH TFA
  • HY-N1391R
    10-Deacetyltaxol (Standard)

    10-Deacetylpaclitaxel (Standard)

    		 Reference Standards Microtubule/Tubulin Cancer
    10-Deacetyltaxol (Standard) is the analytical standard of 10-Deacetyltaxol. This product is intended for research and analytical applications. 10-Deacetyltaxol (10-Deacetylpaclitaxel) is a taxane derivative isolated from Taxus wallichiana Zucc . 10-Deacetyltaxol (10-Deacetylpaclitaxel) promotes the polymerization of tubulin and to inhibit the depolymerization of microtubules induced by cold or by calcium ions in vitro . 10-Deacetyltaxol (10-Deacetylpaclitaxel) exhibits cytotoxicity in human glial and neuroblastoma cell-lines .
    10-Deacetyltaxol (Standard)
  • HY-N0060AR
    Ferulic acid sodium (Standard)

    Coniferic acid sodium (Standard)

    		 Reference Standards FGFR Endogenous Metabolite Reactive Oxygen Species (ROS) Cardiovascular Disease Cancer
    10-Deacetyltaxol (Standard) is the analytical standard of 10-Deacetyltaxol. This product is intended for research and analytical applications. 10-Deacetyltaxol (10-Deacetylpaclitaxel) is a taxane derivative isolated from Taxus wallichiana Zucc . 10-Deacetyltaxol (10-Deacetylpaclitaxel) promotes the polymerization of tubulin and to inhibit the depolymerization of microtubules induced by cold or by calcium ions in vitro . 10-Deacetyltaxol (10-Deacetylpaclitaxel) exhibits cytotoxicity in human glial and neuroblastoma cell-lines .
    Ferulic acid sodium (Standard)
  • HY-123439
    FTY720-C2

    		α-synuclein Neurological Disease
    FTY720-C2 is a derivative of FTY72 (HY-12005). FTY720-C2 promotes the expression of brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) in multiple system atrophy (MSA) models, without causing immunosuppression. FTY720-C2 improves motor dysfunction and reduces the levels of insoluble alpha-synuclein (αSyn) in MSA mouse models. FTY720-C2 is blood-brain barrier penetrate .
    FTY720-C2
  • HY-B0696S
    Tiagabine-d6

    NO050328-d6; NO328-d6; TGB-d6

    		 Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Tiagabine-d6 (NO050328-d6) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine-d6
  • HY-B0696AS
    Tiagabine-d4 hydrochloride

    NO050328-d4 hydrochloride; NO328-d4 hydrochloride; TGB-d4 hydrochloride

    		 Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Tiagabine-d4 hydrochloride is deuterated labeled Tiagabine hydrochloride (HY-B0696A). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine-d4 hydrochloride
  • HY-B0696AR
    Tiagabine hydrochloride (Standard)

    NO050328 hydrochloride (Standard); NO328 hydrochloride (Standard); TGB hydrochloride (Standard)

    		 Reference Standards GABA Receptor Neurological Disease
    Tiagabine (hydrochloride) (Standard) is the analytical standard of Tiagabine (hydrochloride). This product is intended for research and analytical applications. Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine hydrochloride (Standard)
  • HY-183352
    BuChE-IN-23

    		Cholinesterase (ChE) Toll-like Receptor (TLR) p38 MAPK Interleukin Related Complement System Neurological Disease
    BuChE-IN-23 is an orally active, blood-brain barrier permeable butyrylcholinesterase (eqBuChE) inhibitor with an IC50 of 15.59 μM and a Ki of 29.33 μM. BuChE-IN-23 exhibits an IC50 of 38.65 μM against hBuChE and shows selectivity for butyrylcholinesterase over acetylcholinesterase. BuChE-IN-23 inhibits LPS (HY-D1056)-induced nitric oxide production, attenuates hippocampal glial cell activation and neuroinflammation, suppresses the TLR4/p38 MAPK signaling pathway, and regulates the IL-1β/C3-mediated microglia-astrocyte inflammatory axis. BuChE-IN-23 can be used for the research of Alzheimer's disease .
    BuChE-IN-23
  • HY-174566
    Human NRG2 mRNA

    		mRNA Neurological Disease
    Human NRG2 mRNA encodes the human neuregulin 2 (NRG2) protein, a novel member of the neuregulin family of growth and differentiation factors. Through interaction with the ERBB family of receptors, NRG2 can induce the growth and differentiation of epithelial, neuronal, glial, and other types of cells.
    Human NRG2 mRNA
  • HY-182648
    K811

    		Neurological Disease
    K811 is an orally active ASK1 inhibitor with an IC50 of 6 nM. K811 inhibits glial cell activation in the lumbar spinal cord of SOD1 G93A transgenic mice. K811 extends the survival of SOD1 G93A transgenic mice, a mouse model of amyotrophic lateral sclerosis. K811 can be used in studies related to amyotrophic lateral sclerosis .
    K811
  • HY-167983
    Cx43 HC-IN-1

    		Gap Junction Protein Neurological Disease
    Cx43 HC-IN-1 (Compound D4) is a selective and orally active inhibitor of connexin hemichannels (Cx43 HC). Cx43 HC-IN-1 effectively inhibits the hemichannel activity mediated by Cx43/Cx45 in denervated skeletal muscle fibers, significantly increasing the reinnervation rate of muscle fibers by neurons. Cx43 HC-IN-1 reduces neuroinflammation and neuronal overexcitation by inhibiting hemichannels in glial cells in the brain, and alleviates epilepsy in mice. Cx43 HC-IN-1 can be used for research on epilepsy and muscle diseases .
    Cx43 HC-IN-1
  • HY-158252S
    Tiagabine-d5 hydrochloride

    NO050328-d5 hydrochloride; NO328-d5 hydrochloride; TGB-d5 hydrochloride

    		 Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Tiagabine-d5 (hydrochloride) is deuterium labeled Tiagabine (hydrochloride). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine-d5 hydrochloride
  • HY-B0696S1
    Tiagabine-d4

    NO050328-d4; NO328-d4; TGB-d4

    		 Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Tiagabine-d4 (NO050328-d4) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine-d4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: